Sabrina Ranero Ferrari, Hematologist at COSEM IAMPP and Dirección de Sanidad Policía Nacional, Steering Committee at Women in Lymphoma, shared Joaquín Díaz-Schmidt’s, Director of the Medical Subspecialty Program in Hematology at Faculty of Medicine, Clínica Alemana Universidad del Desarrollo and Hematologist, Lymphoma and CLL Program at Clínica Alemana de Santiago, post on X, adding:
“HD-MTX for CNS prophylaxis in high-risk DLBCL? The answer is finally here.
3-yr CNS relapse: 6.6% (HD-MTX) vs 6.7% (no HD-MTX). Adjusted HR 0.95 (0.62–1.44).
Isolated CNS relapse: HR 0.81 (0.50–1.33).
n=1,923 UHR patients. No difference. None.
Time to move on.”
Quoting Joaquín Díaz-Schmidt’s post:
“I think this is the best evidence we’re going to get, and it probably settles the issue. We need to move forward with different strategies.
Congratulations to the authors!”
Title: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Authors: Matthew R. Wilson, Katharine L. Lewis, Amy A. Kirkwood, Kate Cwynarski, Chan Y. Cheah, Tarec C. El-Galaly, Diego Villa, Kerry J. Savage, Paola Ghione, Sabela Bobillo, Karin E. Smedby, Sara Harrysson, Marek Trneny, Magdalena Klanova, Robert Puckrin, Christopher P. Fox, Mark Bishton, Gita Thanarajasingam, Nicole Wong Doo, Greg Hapgood, Carole Soussain, Sylvain Choquet, Michael Dickinson, Dipti Talaulikar, Sanjay de Mel, Gavin Preston, Matthew Ahearne, Eliza A. Hawkes, Elisabeth Schorb, Aline Clavert, Matthew Ku, Anna Guidetti, Mayur Narkhede, Teresa Calimeri, Eric Durot, Jeffrey Smith, Loïc Renaud, Pamela McKay, Toby A. Eyre
Other articles featuring Sabrina Ranero Ferrari on OncoDaily.